Functional inhibition of erectile process in rats by indomethacin.
Despite the important role played by prostaglandins in the control of erection, the potential contribution of non-steroidal anti-inflammatory drugs in erectile dysfunction in experimental animals has not been investigated. We examined the effect of the selective COX-2 inhibitor, celexocib, and the non-selective COX-inhibitors, indomethacin and diclofenac on erectile process in vivo. Erectile responses to electrical stimulation of the cavernous nerve in anesthetized male rats were recorded after single and repeated administration and intracavernosal pressure/mean arterial pressure (ICP/MAP) was calculated. The effect on blood pressure during erection and total plasma nitrite/nitrate level was also investigated. Single-dose administration of indomethacin significantly reduced erectile responses to electrical stimulation at all frequencies tested; 15 mg/kg further reduced ICP/MAP to 0.016 ± 0.005 compared to 0.064 ± 0.012 and 0.104 ± 0.035 for indomethacin (5 mg/kg) and control, respectively at 0.5 Hz. Longer-term treatment with indomethacin completely abolished erectile responses at low frequencies and significantly reduced ICP/MAP at higher frequencies, accompanied by significant reduction in total plasma nitrite/nitrate level. Diclofenac reduced erectile responses only at low frequencies in contrast to celexocib that failed to negatively affect erectile responses. Indomethacin, and to a lower extent diclofenac, may adversely affect erectile responses in rats.